MMED MiniMed Group, Inc.

On September 1, 2026, MiniMed Group, Inc. (NASDAQ:MMED) reported first-quarter fiscal 2027 results for the period ended July 31, 2026. Worldwide net sales rose 16.6% as reported and 15.8% organically to $843 million, U.S. net sales grew 13.1%, and management raised full-year organic revenue growth guidance to approximately 10.5% from 10%. Bulls: Every New Product […]

On September 1, MiniMed (NASDAQ:MMED) reported its first full quarter as a stand-alone public company, and the numbers suggest the split from Medtronic is already paying off. Revenue jumped 15.8% to $843 million, and management raised its full-year growth outlook just months after the IPO roadshow. The catalyst is simple. A new pump finally shipped, […]

Flex pump launch drives 15.8% revenue growth and guidance raise.

It easily topped analyst revenue estimates in its opening quarter of fiscal 2027.

MiniMed Group (NasdaqGS: MMED) reported a strong start to fiscal 2027, with management pointing to accelerated U.S. growth and broader international uptake. The company highlighted progress on next generation products, including trial completions that support its device pipeline. Regulatory updates included advancements with both FDA and CE Mark processes, alongside an improved revenue outlook for the fiscal year. For investors tracking how medical technology and software are reshaping...

Companies In The News Are: MDT, MMED, NIO, AAPL.

MiniMed Group (NASDAQ:MMED) saw its share price increase by 10.66 percent on Tuesday to finish at $22.42 apiece after reporting strong revenues and earning a price target upgrade from an investment firm. In an earnings call on the same day, the company said that it was able to grow its revenues in the first quarter […]

Pfizer gained on vaccine and oncology growth, MiniMed on strong earnings, and Deere on AI-driven agriculture.

Minimed Group Inc (MMED) reports 15.8% organic revenue growth in Q1 2027, driven by successful product launches and robust international performance, while raising its full-year outlook.

Medtronic stock popped Tuesday as its diabetes spinoff MiniMed rallied after both lifted their full-year guidance.

Medtronic stock advances after the company posts better-than-expected quarterly earnings, raises revenue guidance, and announces a $700 million investment.

MiniMed’s first-quarter sales rose 17% to $843 million, while BTIG upgraded Tidewater to ‘Buy’ from ‘Neutral’.

Healthcare stocks were higher Tuesday afternoon, with the NYSE Healthcare Index adding 0.7% and the

MiniMed (MMED) reported a breakeven in fiscal Q1, compared with a loss a year earlier, as net sales

MiniMed Group (NASDAQ:MMED) reported fiscal 2027 first-quarter revenue of $843 million, with organic revenue growth of 15.8%, as demand for its newer insulin-delivery and continuous glucose monitoring products supported growth in the United States and international markets. Chief Executive Officer

Two healthcare innovators, MiniMed Group, Inc. (NASDAQ:MMED) and Abbott Laboratories (NYSE:ABT), hit the spotlight this August with a milestone partnership. On August 17, MiniMed announced that its MiniMed Flex system is commercially shipping in the U.S., integrated with Abbott’s Instinct continuous glucose sensor. This collaboration marks a major leap in diabetes tech, pairing MiniMed’s smallest, […]

MMED's MiniMed Flex is now shipping in the U.S. with Abbott's 15-day Instinct sensor, pairing discreet app control with automated insulin delivery.

Medtronic could finally be on the cusp of a long-awaited turnaround.

MiniMed expands Flex access to Medicare beneficiaries, widening availability of its app-controlled pump and automated insulin delivery technology.